Oral Lichenoid Lesion
Conditions
Interventions
Experimental group:Prednisone tablet, 5mg/ tablet, once a day in the morning, 3 tablets each time (for 2 weeks), once a day in the morning in the 3rd week, 2 tablets each time (for 1 week), once a day
Sponsors
Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) at least 18 years of age; (2) The patient was diagnosed with oral lichenoid lesions according to medical history, clinical manifestations and pathological examination, and the VAS score was =1; (3) The patient participate in the trial voluntarily, can participate in the trial review on time and can complete the whole trial steps; (4) Patients agree to participate in the trial and voluntarily sign informed consent, and can voluntarily provide personal medical history.
Exclusion criteria
Exclusion criteria: (1) Individuals who are allergic to the drugs used in this study or have an allergic constitution; (2) Patients with other identified oral mucosal diseases, or oral lichenoid lesions classified as asymptomatic leukoplakia, or with severe dysplasia or canceration; (3) Patients with serious systemic diseases or tumors; (4) Participants in other clinical trials within the past 3 months; (5) Individuals with oral lichenoid reactions who exposed to certain drugs or silver amalgam fillings; (6) Pregnant and lactating women and those who intend to become pregnant during the trial (according to the information provided by the subject); (7) Patients who need to take antibiotics, hormones, non-steroidal anti-inflammatory drugs, immunosuppressants, immunoenhancers, cytotoxic drugs, cell cycle drugs or anticoagulant drugs that affect oral mucosa regularly due to other chronic diseases, including after transplantation; (8) Serious alcohol and tobacco addicts (drinking >15 units per week, each unit refers to: 350ml beer or 150ml wine or 50ml spirits; Smoking >25 cigarettes/day); (9) Any mental illness, or any other illness which may result in a legal determination of limited capacity.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (reticular, erythema and ulcerative, REU) scores; | — |
Secondary
| Measure | Time frame |
|---|---|
| visual analog scale, VAS;Thongprasom scores;Efficacy indices, El; | — |
Countries
China
Contacts
Public ContactGuoyao Tang
Xinhua Hospital, Shanghai Jiaotong UniversitySchool of Medicine
Outcome results
None listed